Survodutide
Dual GLP-1/Glucagon Receptor Agonist | Weight Reduction & Diabetes
On this page
What is Survodutide?
Survodutide is a lab-made peptide that activates two hormone receptors at once — GLP-1 and glucagon — a dual-agonist mechanism researchers study for metabolic and weight-management research. It remains an investigational compound with no FDA approval, tested so far only in clinical trials. Research-grade survodutide sold here is intended for laboratory study only, not for use in people or animals, and is not a substitute for an approved medication.
Key terms:
Survodutide is a dual glp-1/glucagon receptor agonist (synthetic peptide).
Survodutide (BI 456906) is a lab-made peptide of 29 amino acids, modified with a C18 fatty acid (acylation). It is investigational, not approved, and is given once weekly under the skin. It acts on two receptors at once: GLP-1 (a gut hormone that influences appetite) and glucagon (which affects how the body burns energy). The GLP-1 side lowers energy intake; the glucagon side raises energy expenditure. Researchers report robust results in clinical trials for obesity and for MASH, metabolic dysfunction-associated steatohepatitis.
Key research areas
- Dual mechanism studied for weight-reduction effects
- Once-weekly dosing
- Demonstrated efficacy in obesity/MASH/T2D
- Well-established safety profile from Phase 2/3 trials
Researched dosing
This table reflects how researchers structure survodutide study designs — the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Obesity studies — starting dose | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | Subcutaneous |
| Obesity studies — standard protocol | 3.6-6.0mg | Once weekly | Subcutaneous (abdomen/thigh) |
| MASH studies | 2.4-4.8mg | Once weekly | Subcutaneous |
| Type 2 diabetes studies | 0.3-2.7mg | Once weekly | Subcutaneous |
Commonly cycled 76 weeks on, 0+ weeks off.
How it works
At the cell level, survodutide research looks at how the peptide activates both glucagon and GLP-1 receptors together — one pathway associated with slowing digestion and appetite signals, the other with increasing energy expenditure.
Balanced agonism of glucagon receptors (increases energy expenditure, hepatic fat oxidation) and GLP-1 receptors (reduces appetite, slows gastric emptying) with ~6-day half-life enabling weekly dosing.
Pharmacokinetics
This chart plots how long a research dose of survodutide stays active in the literature; its roughly week-long clearance curve is part of why trial protocols use once-weekly dosing.
- Peak
- 48 hr
- Half-life
- 156 hrs
- Cleared
- ~780 hrs
Phase 2 Clinical Trial Data (Boehringer Ingelheim)
Research applications
This section lists the research areas — metabolic and weight-management research chief among them — that scientists have studied for survodutide in clinical trials; survodutide is investigational, not FDA-approved, and research-grade material sold here is intended for laboratory study only, not a substitute for an approved medication.
Weight Reduction
Phase 2 trial reported 14.9% mean weight reduction at 46 weeks with 4.8mg dose, with 55% achieving ≥15% weight reduction. Greater weight reduction vs semaglutide (-8.7% vs -5.3%) was reported at 16 weeks in a head-to-head trial. Dual mechanism addresses both energy intake and expenditure, potentially reducing weight regain.
Metabolic
In 293 participants with biopsy-confirmed MASH and fibrosis F1-F3, survodutide improved MASH without worsening fibrosis in 47-62% vs 14% placebo. Liver fat reduction ≥30% occurred in 63-67% of treated patients.
Cardiovascular
Clinical trials showed improvements in metabolic risk factors including lipid profiles and glycemic control relevant to cardiovascular health.
Dosage reference
- Doses used in research
- Published trials started at 0.6 mg, adding 0.6 mg every 4 weeks up to 3.6–4.8 mg, with 6.0 mg as the highest step.
- Frequency in studies
- Once weekly on the same day each week
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Weight Reduction begins week 4-8, peak effects after reaching target dose (week 24+)
- Storage
- Refrigerate at 2-8°C, protect from light, use within 4 weeks of reconstitution
- Cycle length
- Long-term therapy - trials up to 76 weeks, likely continuous use
- Break between cycles
- No cycling required - continuous weekly therapy
Interactions
This list shows which other metabolic-research peptides scientists study alongside survodutide, and flags pairings that call for extra caution in a research setting.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried survodutide powder into a liquid research solution used in published study protocols.
- Remove survodutide vial from refrigerator and allow to reach room temperature (15-30 minutes)
- Clean rubber stoppers of both vials with alcohol swabs
- Draw prescribed amount of bacteriostatic water into syringe
- Insert needle into survodutide vial at 45-degree angle
- Slowly inject BAC water down the side of vial to minimize foaming
- Gently swirl vial - do not shake vigorously
- Allow to sit for 2-3 minutes for complete dissolution
- Solution should be clear to slightly opalescent without particles
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: 2-8°C, use within As per manufacturer
Reconstituted: 2-6°C, use within 4 weeks
Open the Survodutide reconstitution calculatorQuality indicators
This section lists what researchers check on a lab report or sample to confirm survodutide's purity and identity before it's used in a study.
Clear to slightly opalescent solution - Properly reconstituted survodutide should be clear or have slight opalescence without visible particles
Sealed vial with intact rubber stopper - Ensures sterility and proper storage conditions have been maintained
Within expiration date - Check both powder and bacteriostatic water expiration dates before use
Slight foam after reconstitution - Normal if disappears within minutes - allow to settle before drawing dose
Cloudy solution or visible particles - Do not use - may indicate contamination or degradation
Discoloration of powder or solution - Should be white to off-white powder and colorless solution when reconstituted
What to expect
This timeline reflects what the clinical-trial literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Possible nausea, reduced appetite - most common during dose escalation
Initial weight reduction begins, improved satiety between meals
Progressive weight reduction, potential improvement in energy levels
Approaching steady-state levels, more consistent effects
Sustained weight reduction, metabolic improvements become more apparent
Safety notes
This section summarizes survodutide's regulatory status and handling notes — research-use-only scope and safety data drawn from the clinical literature, provided as reference context for laboratory researchers, not medical guidance.
- Not recommended in pregnancy or breastfeeding - use contraception
- Monitor blood glucose if on diabetes medications - may need adjustment
- Heart rate may increase slightly (mean 2-5 bpm) - monitor if cardiac conditions
- Investigational compound - not approved by FDA; Phase 2/3 clinical trial data available
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is Survodutide?
Survodutide (BI 456906) is a lab-made peptide that activates two hormone receptors at once — GLP-1 and glucagon — a dual-agonist mechanism studied in metabolic research. It is a 29-amino-acid peptide with C18 fatty-acid acylation and remains an investigational compound with no FDA approval. Lux BioPure supplies research-grade survodutide strictly for laboratory study, not for use in people or animals.
What class of compound is survodutide?
Survodutide is classified as a dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist. In the research literature it is described as a 29-amino-acid peptide carrying a C18 fatty-acid acylation, a modification associated with its roughly week-long duration of action. It is designed for once-weekly subcutaneous administration in published study protocols and remains investigational rather than approved.
How is survodutide typically reconstituted for research use?
In the laboratory, a survodutide vial is brought to room temperature and its rubber stopper cleaned with an alcohol swab. Bacteriostatic water is injected slowly down the side of the vial to minimize foaming, then the vial is gently swirled rather than shaken. A properly prepared solution appears clear to slightly opalescent without visible particles. This is standard research methodology, not a usage instruction.
How should survodutide be stored in the lab?
Lyophilized survodutide is kept refrigerated at 2–8°C and protected from light. Once reconstituted with bacteriostatic water, the solution is refrigerated near 2–6°C and typically used within about four weeks, with the vial labeled by date and concentration for laboratory research use only. A good sample stays clear to slightly opalescent, with cloudiness or discoloration signaling degradation.
Is survodutide legal to purchase for research in Canada?
Lux BioPure sells survodutide in Canada strictly as a research-use-only chemical for laboratory study — it is not for human or veterinary use and is not offered as a drug or supplement. Survodutide is an investigational compound not approved by the FDA, characterized so far only in clinical-trial research, and the research-grade material here is not a substitute for an approved medication.
References
In 387 participants with BMI ≥27 kg/m² without diabetes, survodutide 4.8mg achieved mean 14.9% weight reduction vs 2.8% placebo. 83% achieved ≥5% weight reduction, 69% achieved ≥10%, and 55% achieved ≥15% weight reduction.
View StudyIn 293 participants with biopsy-confirmed MASH and fibrosis F1-F3, survodutide improved MASH without worsening fibrosis in 47% (2.4mg), 62% (4.8mg), and 43% (6.0mg) vs 14% placebo. Liver fat reduction ≥30% occurred in 63-67% of treated patients.
View StudyHead-to-head comparison showed survodutide achieved greater weight reduction than semaglutide 1.0mg after 16 weeks (-8.7% vs -5.3%). HbA1c reductions were dose-dependent, reaching -1.6% with highest doses.
View Study